Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Acorda Therapeutics revenue
Acorda Therapeutics's revenue is $117.6 million.
What is Acorda Therapeutics's revenue?
- Acorda Therapeutics's revenue growth from 2005 to 2023 is 2,186.13%.
- Acorda Therapeutics has 344 employees, and the revenue per employee ratio is $341,956.
- Acorda Therapeutics's peak quarterly revenue was $188.4M in 2017(q4).
- Acorda Therapeutics peak revenue was $588.3M in 2017.
- Acorda Therapeutics annual revenue for 2022 was 118.6M, -8.14% growth from 2021.
- Acorda Therapeutics annual revenue for 2023 was 117.6M, -0.79% growth from 2022.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Acorda Therapeutics historical revenue
Acorda Therapeutics's peak revenue was $588.3M in 2017. The peak quarterly revenue was $188.4M in 2017(q4).
Acorda Therapeutics's revenue increased from $5.1m in 2005 to $117.6M currently. That's a 2,186.13% change in annual revenue.
Acorda Therapeutics annual revenue
Acorda Therapeutics annual revenue over time
| Fiscal year / year | Acorda Therapeutics revenue |
|---|---|
| 2009 | $54.7M |
| 2010 | $191.0M |
| 2011 | $292.2M |
| 2012 | $305.8M |
| 2013 | $336.4M |
| 2014 | $401.5M |
| 2015 | $492.7M |
| 2016 | $519.6M |
| 2017 | $588.3M |
| 2018 | $471.4M |
| 2019 | $192.4M |
| 2020 | $153.0M |
| 2021 | $129.1M |
| 2022 | $118.6M |
| 2023 | $117.6M |
Rate Acorda Therapeutics' financial transparency
Acorda Therapeutics annual growth
Acorda Therapeutics saw the greatest revenue growth in 2006, when revenue increased by 431.55%.
Acorda Therapeutics had the lowest revenue growth in 2019, when revenue changed by -59.19%.
Acorda Therapeutics annual growth rate over time
| Year | Acorda Therapeutics growth |
|---|---|
| 2009 | 14%↑ |
| 2010 | 249%↑ |
| 2011 | 53%↑ |
| 2012 | 5%↑ |
| 2013 | 10%↑ |
| 2014 | 19%↑ |
| 2015 | 23%↑ |
| 2016 | 5%↑ |
| 2017 | 13%↑ |
| 2018 | -20%↓ |
| 2019 | -59%↓ |
| 2020 | -20%↓ |
| 2021 | -16%↓ |
| 2022 | -8%↓ |
| 2023 | -1%↓ |
Acorda Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Acorda Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2009 | ($2.1M) | ($2.2M) | $15.2M | $14.4M |
| 2010 | $493,000 | ($608.0K) | $63.6M | $66.8M |
| 2011 | $61.3M | $65.3M | $93.0M | $72.6M |
| 2012 | $71.2M | $75.7M | $77.4M | $81.5M |
| 2013 | $71.9M | $87.1M | $84.9M | $92.6M |
| 2014 | $80.5M | $97.1M | $106.0M | $117.9M |
| 2015 | $99.9M | $113.7M | $148.2M | $130.9M |
| 2016 | $115.9M | $127.5M | $135.6M | $140.6M |
| 2017 | $119.4M | $139.4M | $141.1M | $188.4M |
| 2018 | $106.2M | $153.3M | $142.8M | $69.2M |
| 2019 | $44.1M | $50.1M | $47.7M | $50.5M |
| 2020 | $28.1M | $33.6M | $53.1M | $38.2M |
| 2021 | $28.9M | $31.8M | $31.5M | $37.0M |
| 2022 | $22.5M | $31.1M | $33.5M | $31.5M |
| 2023 | $22.3M | $29.7M | $27.7M | $38.0M |
| 2024 | $20.3M | - | - | - |
Acorda Therapeutics jobs nearby
Do you work at Acorda Therapeutics?
Is Acorda Therapeutics transparent about its revenue structure?
Acorda Therapeutics financial information
| CEO | Ronald Cohen |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 344 |
| Date Founded | 1995 |
| Headquarters | Ardsley, New York |
| Number of Locations | 3 |
| Revenue | $117.6M |
| Net Income | -$65,916,000 |
| Gross Proft | $102.4M (2023) |
| EBITDA | ($234.3M) (2023) |
| PE Ratio | -3.21 |
| Tax Rate | 0.1% |
| Market Capitalization | $810.9M |
| Total Assets | $395,595,000 |
| Ticker | ACOR |
Acorda Therapeutics jobs you might like
Acorda Therapeutics financing
Acorda Therapeutics received early financing of $2.0M on 1997-10-10.
| Series | Round size | Date |
|---|---|---|
| Grant | $2M | 10/1997 |
| Series A | $33.7M | 01/2001 |
| Series A | $6M | 03/2001 |
| Grant | $100K | 08/2001 |
| Grant | $139K | 08/2002 |
| Grant | $980K | 12/2002 |
| Series B | $55.3M | 05/2003 |
| Grant | $380K | 10/2003 |
| Series Unknown | $11.5M | 03/2004 |
| Post Ipo Equity | $31.5M | 10/2006 |
| Post Ipo Equity | $10M | 11/2006 |
| Post Ipo Equity | $5M | 02/2007 |
Acorda Therapeutics investors
| Investors | Security type |
|---|---|
| Forward Ventures | Series A |
| Baystar Capital | Series A |
| Swiss Life Private Equity Partners | Series A |
| Merrill Lynch Ventures | Series A |
| National Science Foundation SBIR STTR | Grant |
| National Science Foundation SBIR STTR | Grant |
| National Science Foundation SBIR STTR | Grant |
| Forward Ventures | Series B |
| JPMorgan Chase & Co. | Series B |
| Forbion Capital Partners | Series B |
| Cross Atlantic Partners | Series B |
| MPM Capital | Series B |
| ABN AMRO Bank | Series B |
| Easton Capital Investment Group | Series B |
| New York State Department of Health | Grant |
| National Institute of Neurological Disorders and Stroke (NINDS) | Grant |
| Paul Capital Partners | Post Ipo Equity |
| Paul Capital Partners | Post Ipo Equity |
Acorda Therapeutics competitors
Acorda Therapeutics's top competitor, Merck, earned an annual revenue of $64.2B.
Acorda Therapeutics's smallest competitor is Centocor with revenue of $110.0M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 854 |
| Merck | $90,328 | $64.2B | 74,000 | 1,557 |
| Regeneron | $85,589 | $14.2B | 9,123 | 381 |
| Seagen | $85,008 | $2.0B | 900 | - |
| Sanofi Genzyme | $84,495 | $4.6B | 12,000 | - |
| Human Genome Sciences | $70,157 | $131.0M | 1,000 | - |
| Exelixis | $108,978 | $2.2B | 484 | 184 |
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 300 |
| Amgen | $93,349 | $33.4B | 22,000 | 697 |
| Centocor | $73,664 | $110.0M | 3,000 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Acorda Therapeutics highest paying jobs
Zippia gives an in-depth look into the details of Acorda Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Acorda Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Acorda Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Acorda Therapeutics. The data presented on this page does not represent the view of Acorda Therapeutics and its employees or that of Zippia.
Acorda Therapeutics may also be known as or be related to Acorda Therapeutics, Acorda Therapeutics Inc, Acorda Therapeutics Inc. and Acorda Therapeutics, Inc.